Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | SDHB | P21912 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27031498 | 0.88 | DGAT1 (0.46) | SCN9AKIF11CYP11B2SDHBDGAT1 | |
| SCHEMBL18865498 | 0.86 | CYP11B2 (0.42) | SCN9AKIF11CYP11B2SDHBDGAT1 | |
| SCHEMBL18865809 | 0.84 | CYP11B2 (0.47) | SCN9AKIF11CYP11B2SDHBUSP1 | |
| SCHEMBL18886551 | 0.83 | DGAT1 (0.43) | SCN9ACYP11B2SDHBDGAT1KDM4E | |
| SCHEMBL24185774 | 0.82 | DGAT1 (0.49) | SCN9ADGAT1USP1PTGS2KDM4E | |
| SCHEMBL25792141 | 0.82 | DGAT1 (0.43) | SCN9AKIF11DGAT1USP1PTGS2 | |
| SCHEMBL25791923 | 0.82 | DGAT1 (0.43) | SCN9AKIF11DGAT1USP1PTGS2 | |
| SCHEMBL11622203 | 0.81 | PTGS2 (0.51) | DGAT1USP1PTGS2KDM4EPTGS1 | |
| SCHEMBL25180777 | 0.80 | USP1 (0.42) | KIF11CYP11B2SDHBUSP1PTGS2 | |
| SCHEMBL25466455 | 0.79 | USP1 (0.51) | DGAT1USP1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543890-A1 | USP1 INHIBITORS AND USES THEREOF | Forma Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119731178-A | USP1 inhibitors and uses thereof | 福马治疗有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024233665-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023250084-A1 | USP1 INHIBITORS AND USES THEREOF | FORMA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | SCN9A 3365/4885KIF11 2281/4885CYP11B2 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.